sec filing
PR
NASDAQ · PRLD
Prelude Therapeutics Incorporated
Healthcare · Biotechnology
$4.57
Up+$0.11 (+2.30%)
Updated Sep 18, 2026, 5:47 PM
SID Score
5.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 89.12M
- P/E ratio
- -0.99
- Dividend yield
- 0.00%
- 52-week range
- $0.98 – $6.83
- Volume
- 533.88K
- Avg. volume
- 1.38M
Price performance
PRLD price history
1M range · 20 trading sessions · Daily adjusted prices
PRLD closed at $4.57 after 20 trading sessions, down 29.69% for the selected period.
- Last close
- $4.57
- Period change
- -29.69%
- Period low
- $4.47
- Period high
- $6.63
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 17, 2026 | $4.79 | $4.91 | $4.49 | $4.57 | 533.88K |
| Sep 16, 2026 | $4.55 | $4.65 | $4.36 | $4.47 | 191.57K |
| Sep 15, 2026 | $4.56 | $4.58 | $4.40 | $4.52 | 263.32K |
| Sep 14, 2026 | $4.60 | $4.68 | $4.50 | $4.59 | 275.34K |
| Sep 11, 2026 | $4.72 | $4.7499 | $4.56 | $4.59 | 520.54K |
| Sep 10, 2026 | $5.04 | $5.22 | $4.64 | $4.67 | 562.22K |
| Sep 9, 2026 | $5.25 | $5.34 | $5.06 | $5.09 | 311.98K |
| Sep 8, 2026 | $5.38 | $5.46 | $5.19 | $5.30 | 257.89K |
| Sep 4, 2026 | $5.19 | $5.519 | $5.19 | $5.46 | 400.29K |
| Sep 3, 2026 | $5.44 | $5.62 | $5.11 | $5.25 | 577.96K |
| Sep 2, 2026 | $5.53 | $5.82 | $5.30 | $5.43 | 355.09K |
| Sep 1, 2026 | $5.55 | $5.61 | $5.25 | $5.49 | 538.44K |
| Aug 31, 2026 | $5.39 | $5.629 | $5.235 | $5.60 | 737.67K |
| Aug 28, 2026 | $6.27 | $6.3788 | $5.42 | $5.47 | 725.23K |
| Aug 27, 2026 | $6.48 | $6.61 | $6.21 | $6.34 | 364.36K |
| Aug 26, 2026 | $6.61 | $6.71 | $6.3701 | $6.56 | 466.28K |
| Aug 25, 2026 | $6.57 | $6.695 | $6.31 | $6.59 | 415.48K |
| Aug 24, 2026 | $6.64 | $6.83 | $6.115 | $6.47 | 515.72K |
| Aug 21, 2026 | $6.56 | $6.8162 | $6.40 | $6.63 | 519.21K |
| Aug 20, 2026 | $5.70 | $6.6496 | $5.70 | $6.50 | 2.44M |
Latest PRLD news
The latest Smart Investors Daily articles mentioning PRLD.
Stock researchCompany · Earnings
Loading stock research…